Although the endothelium co-generates both nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF), the relative contribution from each vasodilator is not clear. In studies where the endothelium is stimulated acutely, EDHF responses predominate in small arteries. However, the temporal relationship between endothelial-derived NO and EDHF over more prolonged periods is unclear but of major physiological importance. Here we have used a classical pharmacological approach to show that EDHF is released transiently compared with NO. Acetylcholine (3 ϫ 10 Ϫ6 mol/l) dilated second-and/or thirdorder mesenteric arteries for prolonged periods of up to 1 h, an effect that was reversed fully and immediately by the subsequent addition of L-NAME (10 Ϫ3 mol/l) but not TRAM-34 (10 Ϫ6 mol/l) plus apamin (5 ϫ 10 Ϫ7 mol/l). When vessels were pretreated with L-NAME, acetylcholine induced relatively transient dilator responses (declining over ϳ5 min), and vessels were sensitive to TRAM-34 plus apamin. When measured in parallel, the dilator effects of acetylcholine outlasted the smooth muscle hyperpolarization. However, in the presence of L-NAME, vasodilatation and hyperpolarization followed an identical time course. In vessels from NOSIII Ϫ/Ϫ mice, acetylcholine induced small but detectable dilator responses that were transient in duration and blocked by TRAM-34 plus apamin. EDHF responses in these mouse arteries were inhibited by an intracellular calcium blocker, TMB-8, and the phospholipase A 2 inhibitor AACOCF3, suggesting a role for lipid metabolites. These data show for the first time that EDHF is released transiently, whereas endothelial-derived NO is released in a sustained manner.arteries; vasodilation; mediators; hyperpolarization; nitric oxide; endothelium-derived hyperpolarizing factor THE ENDOTHELIUM-DERIVED relaxing factor, described in 1980 by Furchgott and Zawadozki (18), is now known to be nitric oxide (NO) (22, 23), formed from the amino acid L-arginine (32). In 1988, reports emerged of a distinct factor released by the endothelium that relaxed blood vessels via a process of hyperpolarization (endothelium-derived hyperpolarizing factor; EDHF) (2,3,15). Since this time, EDHF biology has developed at a rapid pace (9). However, there is still considerable debate about the identity of EDHF. Potential candidates include CYP450 metabolites (17), K ϩ (16), hydrogen peroxide (26), and K ϩ and/or electrical communications through gap junctions (39) and possibly C-type natriuretic peptide (CNP) (13).Much of the evidence supporting a role for EDHF in endothelium-dependent dilation has been derived pharmacologically, for example, by removing other dilatory pathways (NO and prostacyclin), removing the endothelium, removing the ability to hyperpolarize (with high [K ϩ ]), or blocking K ϩ channels with agents such as TRAM-34 plus apamin. Usually, experiments are conducted where the vessels are stimulated acutely and the responses monitored for short periods of time (seconds or minutes). The temporal nature of EDHF is...